Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions.
Reads0
Chats0
TLDR
A review of the commonly used animal models to study SARS-CoV-2 and COVID-19, including a summary of their susceptibility to infection, the spectrum of symptoms elicited, and the potential for drug development in each model is provided in this paper.About:
This article is published in Pharmacology & Therapeutics.The article was published on 2021-06-23 and is currently open access. It has received 14 citations till now. The article focuses on the topics: Population.read more
Citations
More filters
Journal ArticleDOI
SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets
TL;DR: In this paper , the authors examined the effect of coinfection ferret models described in this paper on the ability to prevent the most severe effects of viral coinfections and found that vaccination significantly ameliorated influenza-associated disease by protecting vaccinated animals from severe morbidity after IAV single infection or IAV and SARS-CoV-2 coinfectation.
Journal ArticleDOI
Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant
Ravi Kant,Lauri Kareinen,Teemu Smura,Tobias L. Freitag,Sawan Kumar Jha,Kari Alitalo,Seppo Meri,Tarja Sironen,Kalle Saksela,Tomas Strandin,Anja Kipar,Anja Kipar,Anja Kipar,Olli Vapalahti +13 more
TL;DR: In this article, the SARS-CoV-2 beta variant attains infectibility to BALB/c mice and causes pulmonary changes within 2-3 days post infection, consistent with results seen in other murine models of COVID-19.
Journal ArticleDOI
RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection
TL;DR: In this article , the authors used the K18-hACE2 mouse model to examine whether activation of the antiviral RNA receptor RIG-I protects mice from lethal SARS-CoV-2 infection and reduces disease severity.
Posted ContentDOI
RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection
Samira Marx,Beate M Kuemmerer,Christian Gruetzner,Hiroki Kato,Martin Schlee,Eva Bartok,Eva Bartok,Marcel Renn,Gunther Hartmann +8 more
TL;DR: Results reveal that prophylactic RIG-I activation by synthetic RNA oligonucleotides is a promising strategy to convey short-term, unspecific antiviral protection against SARS-CoV-2 infection and may be a suitable broad-spectrum approach to constraining the spread of newly emerging viruses until virus-specific therapies and vaccines become available.
Journal ArticleDOI
Animal models for studying COVID-19, prevention, and therapy: Pathology and disease phenotypes
TL;DR: An overview of commonly used COVID-19 animal models and the pathologic features of SARS-CoV-2 infection in these models in relation to their clinical presentation in humans is provided.
References
More filters
Journal ArticleDOI
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
Jérôme Hadjadj,Nader Yatim,Laura Barnabei,Aurélien Corneau,Jeremy Boussier,Nikaïa Smith,Hélène Péré,Bruno Charbit,Vincent Bondet,Camille Chenevier-Gobeaux,Paul Breillat,Nicolas Carlier,Rémy Gauzit,Caroline Morbieu,Frédéric Pène,Nathalie Marin,Nicolas Roche,Tali Anne Szwebel,Sarah H. Merkling,Jean-Marc Treluyer,David Veyer,Luc Mouthon,Catherine Blanc,Pierre-Louis Tharaux,Flore Rozenberg,Alain Fischer,Alain Fischer,Alain Fischer,Darragh Duffy,Frédéric Rieux-Laucat,Solen Kernéis,Solen Kernéis,Benjamin Terrier +32 more
TL;DR: The results of this trio of studies suggest that the location, timing, and duration of IFN exposure are critical parameters underlying the success or failure of therapeutics for viral respiratory infections.
Journal ArticleDOI
Extrapulmonary manifestations of COVID-19.
Aakriti Gupta,Aakriti Gupta,Mahesh V. Madhavan,Kartik Sehgal,Kartik Sehgal,Nandini Nair,Shiwani Mahajan,Tejasav S. Sehrawat,Behnood Bikdeli,Behnood Bikdeli,Neha Ahluwalia,John C. Ausiello,Elaine Wan,Daniel E. Freedberg,Ajay J. Kirtane,Sahil A. Parikh,Mathew S. Maurer,Anna S. Nordvig,Domenico Accili,Joan M. Bathon,Sumit Mohan,Kenneth A. Bauer,Kenneth A. Bauer,Martin B. Leon,Harlan M. Krumholz,Nir Uriel,Mandeep R. Mehra,Mitchell S.V. Elkind,Mitchell S.V. Elkind,Gregg W. Stone,Allan Schwartz,David D. Ho,John P. Bilezikian,Donald W. Landry +33 more
TL;DR: The extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 are reviewed to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved.
Journal ArticleDOI
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Paul Bastard,Paul Bastard,Paul Bastard,Lindsey B. Rosen,Qian Zhang,Eleftherios Michailidis,Hans-Heinrich Hoffmann,Yu Zhang,Karim Dorgham,Quentin Philippot,Quentin Philippot,Jérémie Rosain,Jérémie Rosain,Vivien Béziat,Vivien Béziat,Vivien Béziat,Jeremy Manry,Jeremy Manry,Elana Shaw,Liis Haljasmägi,Pärt Peterson,Lazaro Lorenzo,Lazaro Lorenzo,Lucy Bizien,Lucy Bizien,Sophie Trouillet-Assant,Kerry Dobbs,Adriana Almeida de Jesus,Alexandre Belot,Anne Kallaste,Emilie Catherinot,Yacine Tandjaoui-Lambiotte,Jérémie Le Pen,Gaspard Kerner,Gaspard Kerner,Benedetta Bigio,Yoann Seeleuthner,Yoann Seeleuthner,Rui Yang,Alexandre Bolze,András N Spaan,András N Spaan,Ottavia M. Delmonte,Michael S. Abers,Alessandro Aiuti,Giorgio Casari,Vito Lampasona,Lorenzo Piemonti,Fabio Ciceri,Kaya Bilguvar,Richard P. Lifton,Richard P. Lifton,Marc Vasse,David M. Smadja,Mélanie Migaud,Mélanie Migaud,Jérôme Hadjadj,Benjamin Terrier,Darragh Duffy,Lluis Quintana-Murci,Lluis Quintana-Murci,Diederik van de Beek,Lucie Roussel,Donald C. Vinh,Stuart G. Tangye,Stuart G. Tangye,Filomeen Haerynck,David Dalmau,Javier Martinez-Picado,Javier Martinez-Picado,Petter Brodin,Petter Brodin,Michel C. Nussenzweig,Michel C. Nussenzweig,Stéphanie Boisson-Dupuis,Stéphanie Boisson-Dupuis,Stéphanie Boisson-Dupuis,Carlos Rodríguez-Gallego,Guillaume Vogt,Trine H. Mogensen,Trine H. Mogensen,Andrew J. Oler,Jingwen Gu,Peter D. Burbelo,Jeffrey I. Cohen,Andrea Biondi,Laura Rachele Bettini,Mariella D'Angiò,Paolo Bonfanti,Patrick Rossignol,Julien Mayaux,Frédéric Rieux-Laucat,Eystein S. Husebye,Eystein S. Husebye,Eystein S. Husebye,Francesca Fusco,Matilde Valeria Ursini,Luisa Imberti,Alessandra Sottini,Simone Paghera,Eugenia Quiros-Roldan,Camillo Rossi,Riccardo Castagnoli,Daniela Montagna,Amelia Licari,Gian Luigi Marseglia,Xavier Duval,Jade Ghosn,Hgid Lab,Covid Clinicians,Covid-Storm Clinicians§,CoV-Contact Cohort§,Amsterdam Umc Covid Biobank,Amsterdam Umc Covid Biobank,Amsterdam Umc Covid Biobank,Covid Human Genetic Effort,John S. Tsang,Raphaela Goldbach-Mansky,Kai Kisand,Michail S. Lionakis,Anne Puel,Anne Puel,Anne Puel,Shen-Ying Zhang,Shen-Ying Zhang,Shen-Ying Zhang,Steven M. Holland,Guy Gorochov,Emmanuelle Jouanguy,Emmanuelle Jouanguy,Emmanuelle Jouanguy,Charles M. Rice,Aurélie Cobat,Aurélie Cobat,Aurélie Cobat,Luigi D. Notarangelo,Laurent Abel,Laurent Abel,Laurent Abel,Helen C. Su,Jean-Laurent Casanova +140 more
TL;DR: A means by which individuals at highest risk of life-threatening COVID-19 can be identified is identified, and the hypothesis that neutralizing auto-Abs against type I IFNs may underlie critical CO VID-19 is tested.
Journal ArticleDOI
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
Carly G. K. Ziegler,Samuel J. Allon,Sarah K. Nyquist,Ian M. Mbano,Vincent N. Miao,Constantine N. Tzouanas,Yuming Cao,Ashraf S. Yousif,Julia Bals,Blake M. Hauser,Blake M. Hauser,Jared Feldman,Jared Feldman,Christoph Muus,Christoph Muus,Marc H. Wadsworth,Samuel W. Kazer,Travis K. Hughes,Benjamin Doran,G. James Gatter,G. James Gatter,G. James Gatter,Marko Vukovic,Faith Taliaferro,Faith Taliaferro,Benjamin E. Mead,Zhiru Guo,Jennifer P. Wang,Delphine Gras,Magali Plaisant,Meshal Ansari,Ilias Angelidis,Heiko Adler,Jennifer M.S. Sucre,Chase J. Taylor,Brian M. Lin,Avinash Waghray,Vanessa Mitsialis,Vanessa Mitsialis,Daniel F. Dwyer,Kathleen M. Buchheit,Joshua A. Boyce,Nora A. Barrett,Tanya M. Laidlaw,Shaina L. Carroll,Lucrezia Colonna,Victor Tkachev,Victor Tkachev,Christopher W. Peterson,Christopher W. Peterson,Alison Yu,Alison Yu,Hengqi Betty Zheng,Hengqi Betty Zheng,Hannah P. Gideon,Caylin G. Winchell,Philana Ling Lin,Philana Ling Lin,Colin D. Bingle,Scott B. Snapper,Scott B. Snapper,Jonathan A. Kropski,Jonathan A. Kropski,Fabian J. Theis,Herbert B. Schiller,Laure-Emmanuelle Zaragosi,Pascal Barbry,Alasdair Leslie,Alasdair Leslie,Hans-Peter Kiem,Hans-Peter Kiem,JoAnne L. Flynn,Sarah M. Fortune,Sarah M. Fortune,Sarah M. Fortune,Bonnie Berger,Robert W. Finberg,Leslie S. Kean,Leslie S. Kean,Manuel Garber,Aaron G. Schmidt,Aaron G. Schmidt,Daniel Lingwood,Alex K. Shalek,Jose Ordovas-Montanes,Nicholas E. Banovich,Alvis Brazma,Tushar J. Desai,Thu Elizabeth Duong,Oliver Eickelberg,Christine S. Falk,Michael Farzan,Ian A. Glass,Muzlifah Haniffa,Peter Horvath,Deborah T. Hung,Naftali Kaminski,Mark A. Krasnow,Malte Kühnemund,Robert Lafyatis,Haeock Lee,Sylvie Leroy,Sten Linnarson,Joakim Lundeberg,Kerstin B. Meyer,Alexander V. Misharin,Martijn C. Nawijn,Marko Nikolic,Dana Pe'er,Joseph E. Powell,Stephen R. Quake,Jay Rajagopal,Purushothama Rao Tata,Emma L. Rawlins,Aviv Regev,Paul A. Reyfman,Mauricio Rojas,Orit Rosen,Kourosh Saeb-Parsy,Christos Samakovlis,Herbert B. Schiller,Joachim L. Schultze,Max A. Seibold,Douglas P. Shepherd,Jason R. Spence,Avrum Spira,Xin Sun,Sarah A. Teichmann,Fabian J. Theis,Alexander M. Tsankov,Maarten van den Berge,Michael von Papen,Jeffrey A. Whitsett,Ramnik J. Xavier,Yan Xu,Kun Zhang +135 more
TL;DR: The data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.
Journal ArticleDOI
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Vanessa Monteil,Hyesoo Kwon,Patrícia Rezende do Prado,Astrid Hagelkruys,Reiner A. Wimmer,Martin Stahl,Alexandra Leopoldi,Elena Garreta,Carmen Hurtado del Pozo,Felipe Prosper,Juan P. Romero,Gerald Wirnsberger,Haibo Zhang,Arthur S. Slutsky,Ryan K. Conder,Nuria Montserrat,Ali Mirazimi,Ali Mirazimi,Josef M. Penninger,Josef M. Penninger +19 more
TL;DR: It is demonstrated that hrsACE2 can significantly block early stages of SARS-CoV-2 infections, and is proposed that inhibiting this interaction might be used in treating patients with COVID-19.